8-K
filed June 4, 2026, 5:00 PM ET
ticker TPST
CIK 0001544227
leadership
confidence high
sentiment neutral
materiality 0.65
Tempest Therapeutics CFO resigns, appoints new CFO and two independent directors
Tempest Therapeutics, Inc.
- CFO Nicholas Maestas resigns effective June 5, 2026; Justin Trojanowski named VP Finance, Principal Financial Officer and Corporate Secretary.
- Board appoints Drake Richey and John Yee, MD, MPH as Class II independent directors effective June 4, 2026.
- Company received Nasdaq non-compliance notice on May 22 due to board vacancies; believes it can cure with one remaining vacancy.
- Amended director compensation policy reduces annual cash retainers: base $20K, committee chair $5K-$10K, member $2.5K-$5K.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
John David Yee was appointed as Class II Director at Tempest Therapeutics, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Justin Trojanowski was appointed as Vice President, Finance, Principal Financial Officer and Corporate Secretary at Tempest Therapeutics, Inc..
- Action
- appointed
- Role
- Vice President, Finance, Principal Financial Officer and Corporate Secretary
Exact text from the filing
the Board of Directors of the Company (the “Board”) appointed Mr. Justin Trojanowski as Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company, in addition to his current role as Corporate Controller, Treasurer and Principal Accounting Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William Drake Richey was appointed as Class II Director at Tempest Therapeutics, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nicholas Maestas resigned as Chief Financial Officer at Tempest Therapeutics, Inc..
- Action
- resigned
- Role
- Chief Financial Officer
Exact text from the filing
Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.